Viral Gastroenteritis Market Report 2026

The viral gastroenteritis market size has grown strongly in recent years. It will grow from $7.06 billion in 2025 to $7.43 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to improvements in public health awareness, expansion of healthcare access, availability of basic diagnostic tools, increasing use of oral rehydration solutions, improved disease reporting systems.

The viral gastroenteritis market size is expected to see strong growth in the next few years. It will grow to $9.2 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing investments in infectious disease surveillance, rising demand for rapid point-of-care diagnostics, expansion of vaccination and prevention programs, growing focus on pediatric healthcare, increasing adoption of digital disease monitoring. Major trends in the forecast period include increasing focus on rapid diagnostic testing, rising demand for supportive care therapies, growing emphasis on infection control and prevention, expansion of oral rehydration and zinc therapy usage, enhanced surveillance of viral outbreaks.

The increasing prevalence of gastrointestinal disorders is expected to drive the growth of the viral gastroenteritis market in the coming years. Gastrointestinal (GI) disorders refer to diseases affecting any part of the gastrointestinal tract. Viral gastroenteritis treatments help patients manage the illness through appropriate medication and care. For instance, in September 2023, according to the Impact of IBD Report 2023 published by the IBD Clinical and Research Centre, a Canada-based organization dedicated to improving the lives of patients with Crohn’s disease and ulcerative colitis, over 320,000 people in Canada were living with inflammatory bowel disease (IBD), with a prevalence of 825 per 100,000 in 2023. As the prevalence is expected to rise by 2.44% annually, approximately 1.1% of the population, or 470,000 Canadians, is projected to have IBD by 2035. Therefore, the increasing prevalence of gastrointestinal disorders is propelling the growth of the viral gastroenteritis market.

Major companies operating in the viral gastroenteritis market are focusing on developing new products, such as PCR kits for gastrointestinal infectious diseases, to gain a competitive advantage. PCR kits, or Polymerase Chain Reaction kits, are molecular biology tools used for the amplification and detection of specific DNA sequences. For instance, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a China-based molecular diagnostics company, launched 10 Real-Time PCR Kits designed for accurate detection of gastrointestinal pathogens, creating a comprehensive Total PCR Solution when combined with their extraction solution and PCR system. The Real-Time PCR Kits detect a range of bacterial, viral, and parasitic pathogens associated with gastrointestinal infections, including bacteria such as Campylobacter, Salmonella, Shigella, and Clostridioides difficile, as well as viruses like Adenovirus, Rotavirus, Astrovirus, and Norovirus. This solution offers a streamlined workflow from sample pre-processing to PCR amplification analysis.

In January 2024, HilleVax Inc., a Switzerland-based biotech company, collaborated with Chengdu Kanghua Biological Products Co. Ltd. Through this collaboration, HilleVax aims to develop HIL-216, a next-generation norovirus vaccine targeting six common genotypes, with clinical trials scheduled to begin in 2024 following FDA clearance. Chengdu Kanghua Biological Products Co. Ltd. is a China-based company specializing in the development and manufacturing of biological products and vaccines for both veterinary and human health.

Major companies operating in the viral gastroenteritis market are Pfizer Inc., Sanofi S A, Abbott Laboratories, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Mylan N V, Dr Reddys Laboratories Ltd, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd, ANI Pharmaceuticals Inc, Merck Sharp & Dohme Corp, Abbvie Inc, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Roche Holding AG, BristolMyersSquibb Company, Amgen Inc, Eli Lilly and Company, Novartis AG, Johnson and Johnson, Moderna Inc, Bharat Biotech International Ltd.

North America was the largest region in the viral gastroenteritis market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral gastroenteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral gastroenteritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the viral gastroenteritis market by increasing costs of imported diagnostic kits, laboratory reagents, pharmaceutical raw materials, and medical packaging components. Healthcare systems in North America and Europe are most affected due to dependence on imported diagnostics and medicines, while Asia-Pacific faces cost pressure on pharmaceutical manufacturing inputs. These tariffs are increasing treatment and testing costs and impacting procurement budgets. However, they are also encouraging domestic production of diagnostics, local pharmaceutical manufacturing, and strengthened regional supply chains for essential treatments.

The viral gastroenteritis market research report is one of a series of new reports that provides viral gastroenteritis market statistics, including viral gastroenteritis industry global market size, regional shares, competitors with a viral gastroenteritis market share, detailed viral gastroenteritis market segments, market trends and opportunities, and any further data you may need to thrive in the viral gastroenteritis industry. This viral gastroenteritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral gastroenteritis is an intestinal viral infection characterized by swelling, irritation, and inflammation of the inner lining of the gastrointestinal tract. Common signs and symptoms include watery diarrhea, nausea or vomiting, stomach cramps, and fever.

The main types of drugs used in viral gastroenteritis include antibiotics, antacids, laxatives, antimotility agents, and others. Antacids are medications that neutralize stomach acid to relieve heartburn and indigestion. Diagnosis typically involves a physical examination and a rapid stool test, indicated by symptoms such as watery diarrhea, abdominal cramps, and pain. The viruses commonly involved include norovirus, rotavirus, astrovirus, and enteric adenovirus. These treatments and diagnostic methods are used by end users such as hospitals, clinics, pharmaceutical companies, diagnostic centers, ambulatory care centers, and others.

The viral gastroenteritis market consists of revenues earned by entities by providing various diagnostics such as polymerase chain reaction testing and immunoassays. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral gastroenteritis market also includes sales of antiemetics, and chemotherapy drugs used for treating viral gastroenteritis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.